UCSF spinout Mission Bio has pushed its overall funding to more than $120m following a series C round led by Novo Growth.

Mission Bio, a US-based DNA analysis technology spinout of University of California, San Francisco (UCSF), has raised $70m in a series C round led by pharmaceutical firm Novo’s Novo Growth unit.
Agilent Ventures, the corporate venturing arm of laboratory equipment and diagnostics services provider Agilent Technologies, also took part in the round, as did Cota Capital, Mayfield Fund and Soleus Capital.
The round took the company’s total funding to more than $120m, it said, and Robert Ghenchev, head…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in